2019-11-05
ViewReleaseInStandardHtml

For the first time in UK, a wider audience can get first-hand experience of the NeoNavia® micropulse biopsy system for breast cancer

During the annual meeting of the British Society of Breast Radiology (BSBR) on 3-5th November in Bristol, radiologists get to gain first-hand experience using the innovative micropulse technology in meat models via a series of hands-on workshops arranged by NeoDynamics

High interest in the workshops has led to additional sessions being added and over 50 radiologists being able to try the new system.

The BSBR workshops represent a milestone for NeoDynamics and for the first time a wider audience will get to not only hear about the NeoNavia system but try it for themselves.

"With the UK study starting imminently and a commercial launch on the near horizon, the workshops and gaining feedback from potential future customers is extremely valuable and will help us tailor our offering and maximise the patient benefit”, says Ian Galloway, Country Manager in UK for NeoDynamics

“We look forward to starting the multicentre study in UK very soon and with a planned total of 320 patients to be enrolled, there is room for more centres to join. As such, we hope that this meeting and the demo-workshops will spark interest and enthusiasm for our biopsy system and encourage others to participate in the study”, says Kai-Uwe Schässburger, Head of Clinical Development and Medical Affairs.

For further information about NeoDynamics, please contact:                         

Anna Eriksrud, CEO NeoDynamics AB (publ), telephone: +46 8 522 79 667, e-mail: anna.eriksrud@neodynamics.se, or

Jörgen Vrenning, CFO/IR NeoDynamics AB (publ), Telephone: +46 708 519 648, email: jorgen.vrenning@neodynamics.se


About NeoDynamics

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company has an innovative biopsy system, NeoNavia® , in late stage development. The precision biopsy system is built on a patented micro-pulse technology, based on research at the Karolinska Institutet in Sweden. The system is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment. NeoNavia® is evaluated at leading clinics in UK, Germany and Sweden. A commercial launch is expected in 2020.

About NeoNavia

NeoNavia is the brand name for the entire biopsy system intended to be used under ultrasound guidance.  NeoNavia consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the micro-pulses enabling high precision and control when inserting and positioning the biopsy needle in a suspicious lesion. The system is designed to offer accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

About the micro-pulse technology

The patented micro-pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, independent of tissue type. The pneumatic driver that generates micro-pulses is placed in a handheld instrument. With power from the base-unit, the driver accelerates the needle with great control even over a short distance, enabling its distinct stepwise insertion without the risk of destroying surrounding tissue. This facilitates ease of access and flexibility in sampling, even in very small lesions in delicate and difficult locations.